세계의 바이오마커 탐색 아웃소싱 서비스 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커 유형별, 치료 영역별, 페이즈별, 최종 용도별, 지역별 부문 예측(2025-2030년)
Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive, Safety), By Therapeutic Area (Oncology, Neurology), By Phase, By End Use, By Region, And Segment Forecasts, 2025 - 2030
상품코드
:
1678717
리서치사
:
Grand View Research
발행일
:
2025년 02월
페이지 정보
:
영문 150 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
세계의 바이오마커 탐색 아웃소싱 서비스 시장 성장과 동향
Grand View Research, Inc.의 최신 보고서에 따르면 세계의 바이오마커 탐색 아웃소싱 서비스 시장 규모는 2025-2030년까지 CAGR 19.4%로 성장하여 2030년에는 412억 7,000만 달러에 이를 전망입니다.
임상 검사에서 바이오마커 이용 증가와 제약 기업의 아웃소싱 가속으로 인한 바이오마커 조사 아웃소싱 확대는 이 시장의 주요 성장 요인입니다.
또한 액체 생검 도입 증가가 시장 성장을 가속할 것으로 예상됩니다. 혈액, 소변, 뇌척수액과 같은 체액의 바이오마커를 분석하는 액체 바이오시는 기존의 조직 생검에 비해 침습성이 낮고 실시간으로 정보를 얻을 수 있는 등 몇 가지 장점이 있습니다. 그 결과, 리퀴드 바이옵시의 채용은 급속히 확대되고 있으며, 이 동향은 바이오마커 탐색 아웃소싱 서비스 수요에 직접 영향을 미치고 있습니다.
오믹스 기술의 발전은 앞으로 수년간 시장 성장을 가속할 것으로 예상됩니다. 유전체, 단백질체학, 대사체학 및 기타 오믹스 기술의 발전으로 새로운 바이오마커를 확인할 수 있게 되었습니다. 많은 오믹스 부문의 데이터를 통합하는 것은 바이오마커 식별에 유리한 경우가 많습니다. 멀티오믹스 데이터 통합을 전문으로 하는 아웃소싱 서비스는 이 부문에서 귀중한 전문 지식을 제공합니다.
의약품 개발과 임상 검사 증가는 시장 성장의 주요 요인입니다. 바이오마커는 의약품 개발에 중요한 역할을 하고 있으며, 제약 회사가 적절한 창약 표적을 확인하고, 임상 검사 과정을 간소화하고, 검사에 참여할 환자 집단을 선택하는 데 도움을 줍니다. 2023년 현재 세계의 임상검사 상황은 ClinicalTrials.gov에 45만 2,604건의 임상검사가 등록되어 있으며, 6만 4,838명이 적극적으로 참가자를 등록하고 있습니다. 이는 2021년 초에 기록된 약 36만 5,000건의 등록검사에 비해 현저한 급증을 반영하여 임상연구 부문에서의 견조하고 지속적인 성장을 뒷받침하고 있습니다.
바이오마커 탐색 아웃소싱 서비스 시장 보고서 하이라이트
바이오마커 유형별로는 대리 엔드포인트 부문이 2024년 54.88%의 최대 판매 점유율을 차지했습니다.
치료 영역별로는 종양학, 신경학, 순환기학, 자가면역 질환, 기타가 있습니다.
단계별로는, 2024년 바이오마커 식별 부문이 시장에서 가장 큰 수익 점유율을 차지했습니다.
최종 용도별로는 제약 기업, 생명 공학 회사 등으로 구분됩니다.
북미 바이오마커 탐색 아웃소싱 서비스 산업은 2024년 43.96%의 최대 시장 점유율을 차지했습니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 바이오마커 탐색 아웃소싱 서비스 시장의 변수, 동향, 범위
시장 계통의 전망
시장 역학
시장 성장 촉진요인 분석
시장 성장 억제요인 분석
기술
바이오마커 연구에서 AI와 빅데이터의 통합
오믹스 기술
바이오인포매틱스와 클라우드 컴퓨팅의 역할
가격 모델 분석
밸류체인 분석
시장 분석 도구
Porter's Five Forces 분석
SWOT 분석에 의한 PESTEL
COVID-19의 영향 분석
제4장 바이오마커 탐색 아웃소싱 서비스 시장 : 바이오마커 유형별, 추정 및 동향 분석
바이오마커 탐색 아웃소싱 서비스 시장, 바이오마커 유형별 : 부문 대시보드
바이오마커 탐색 아웃소싱 서비스 시장, 바이오마커 유형별 : 변동 분석
바이오마커 유형별, 2018-2030년
예측 바이오마커
예후 바이오마커
안전 바이오마커
대리 엔드포인트
제5장 바이오마커 탐색 아웃소싱 서비스 시장 : 치료 영역별, 추정 및 동향 분석
바이오마커 탐색 아웃소싱 서비스 시장, 치료 영역별: 부문 대시보드
바이오마커 탐색 아웃소싱 서비스 시장, 치료 영역별: 변동 분석
치료 영역별, 2018-2030년
종양학
신경학
심장병학
자가면역질환
기타
제6장 바이오마커 탐색 아웃소싱 서비스 시장 : 위상별, 추정 및 동향 분석
바이오마커 탐색 아웃소싱 서비스 시장, 단계별: 부문 대시보드
바이오마커 탐색 아웃소싱 서비스 시장, 단계별: 변동 분석
페이즈별, 2018-2030년
바이오마커 특정
바이오마커 검증
바이오마커 프로파일링
바이오마커 패널 개발
바이오마커 선택
제7장 바이오마커 탐색 아웃소싱 서비스 시장 : 최종 용도별, 추정 및 동향 분석
바이오마커 탐색 아웃소싱 서비스 시장, 최종 용도별: 부문 대시보드
바이오마커 탐색 아웃소싱 서비스 시장, 최종 용도별: 변동 분석
최종 용도별, 2018-2030년
제약회사
바이오테크놀러지 기업
기타
제8장 바이오마커 탐색 아웃소싱 서비스 시장 : 지역별, 추정 및 동향 분석
지역별 시장 점유율 분석, 2024년과 2030년
지역별 시장 대시보드
세계 지역 시장 현황
북미
유럽
영국
독일
프랑스
이탈리아
스페인
스웨덴
덴마크
노르웨이
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카
사우디아라비아
아랍에미리트(UAE)
쿠웨이트
제9장 경쟁 구도
시장 진출기업의 분류
기업의 시장 점유율/평가 분석, 2024년
기업 프로파일
Laboratory Corporation of America Holdings
Charles River Laboratories
Eurofins Scientific
Celerion
ICON plc.
Parexel International(MA) Corporation
Proteome Sciences
GHO Capital
Thermo Fisher Scientific Inc.
Evotec
JHS
영문 목차
Biomarker Discovery Outsourcing Services Market Growth & Trends:
The global biomarker discovery outsourcing services market size is expected to reach USD 41.27 billion by 2030, growing at a CAGR of 19.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The expansion of outsourced biomarker research, attributed to the increased utilization of biomarkers in clinical trials and the accelerating level of outsourcing undertaken by pharmaceutical firms are key growth factors for this market.
Furthermore, increasing adoption of liquid biopsies is expected to drive the market growth. Liquid biopsies, which involve the analysis of biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid, offer several advantages over traditional tissue biopsies, such as being less invasive and providing real-time information. As a result, the adoption of liquid biopsies has been growing rapidly, and this trend directly impacts the demand for biomarker discovery outsourcing services.
Advancements in omics technologies are expected to drive market growth in the coming years. Progress in genomics, proteomics, metabolomics, and other omics technologies has enabled the identification of novel biomarkers.Integrating data from many omics disciplines can often be advantageous for biomarker identification. This all-encompassing approach enables a more thorough comprehension of complex disorders and can result in identifying reliable, multidimensional biomarkers.Outsourcing services specializing in multi-omics data integration offer valuable expertise in this area.
An increase in drug development and clinical trials is a major contributing factor to the market growth. Biomarkers play a crucial role in drug development, helping pharmaceutical companies identify suitable drug targets, streamline clinical trial processes, and select patient populations for trials.As of 2023, the global clinical trial landscape boasts 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This reflects a notable surge compared to the roughly 365,000 registered trials documented in early 2021, underscoring the robust and ongoing growth within the field of clinical research.
Biomarker Discovery Outsourcing Services Market Report Highlights:
Based on biomarker type, the surrogate endpoints segment accounted for the largest revenue share of 54.88% in 2024.
Based on therapeutic areas, the market includes oncology, neurology, cardiology, autoimmune diseases, and others.
Based on the discovery phase, in 2024, the biomarker identification segment accounted for the largest revenue share in the market.
Based on end use, the market is segmented into pharmaceutical companies, biotechnology companies, and others.
The biomarker discovery outsourcing services industry in North America accounted for the largest market share of 43.96% in 2024.
Table of Contents Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR's Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Biomarker Discovery Outsourcing Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Demand for Biomarkers in Drug Development
3.2.1.2. Expanding R&D Investment in Biopharmaceuticals
3.2.1.3. Rising Prevalence of Chronic and Infectious Diseases
3.2.1.4. Increasing focus on personalized medicine and targeted therapies
3.2.1.5. Advancements in Omics Technologies
3.2.1.6. Increasing Role of CROs and CDMOs Owing to Cost and Time Efficiency
3.2.2. Market Restraint Analysis
3.2.2.1. Limited Reproducibility & Validation Challenges
3.2.2.2. High Cost of Biomarker Discovery & Validation
3.2.2.3. Data Privacy & Security Concerns
3.3. Technology Landscape
3.3.1. Integration of AI and Big Data in Biomarker Research
3.3.2. Omics Technologies
3.3.3. Role of Bioinformatics & Cloud Computing
3.4. Pricing Model Analysis
3.5. Value Chain Analysis
3.6. Market Analysis Tools
3.6.1. Porter's Five Forces Analysis
3.6.2. PESTEL by SWOT Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Biomarker Discovery Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis
4.1. Biomarker Discovery Outsourcing Services Market, By Biomarker Type: Segment Dashboard
4.2. Biomarker Discovery Outsourcing Services Market, By Biomarker Type: Movement Analysis
4.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By Biomarker Type, 2018 - 2030 (USD Million)
4.4. Predictive Biomarkers
4.4.1. Predictive Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Prognostic Biomarkers
4.5.1. Prognostic Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Safety Biomarkers
4.6.1. Safety Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Surrogate Endpoints
4.7.1. Surrogate Endpoints Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Biomarker Discovery Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis
5.1. Biomarker Discovery Outsourcing Services Market, By Therapeutic Area: Segment Dashboard
5.2. Biomarker Discovery Outsourcing Services Market, By Therapeutic Area: Movement Analysis
5.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030 (USD Million)
5.4. Oncology
5.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Neurology
5.5.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Cardiology
5.6.1. Cardiology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Autoimmune Diseases
5.7.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Other Therapeutic Area
5.8.1. Other Therapeutic Area Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Biomarker Discovery Outsourcing Services Market: Discovery Phase Estimates & Trend Analysis
6.1. Biomarker Discovery Outsourcing Services Market, By Discovery Phase: Segment Dashboard
6.2. Biomarker Discovery Outsourcing Services Market, By Discovery Phase: Movement Analysis
6.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By Discovery Phase, 2018 - 2030 (USD Million)
6.4. Biomarker Identification
6.4.1. Biomarker Identification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Biomarker Validation
6.5.1. Biomarker Validation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Biomarker Profiling
6.6.1. Biomarker Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Biomarker Panel Development
6.7.1. Biomarker Panel Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Biomarker Selection
6.8.1. Biomarker Selection Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Biomarker Discovery Outsourcing Services Market: End Use Estimates & Trend Analysis
7.1. Biomarker Discovery Outsourcing Services Market, By End Use: Segment Dashboard
7.2. Biomarker Discovery Outsourcing Services Market, By End Use: Movement Analysis
7.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
7.4. Pharmaceutical Companies
7.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Biotechnology Companies
7.5.1. Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Others
7.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Biomarker Discovery Outsourcing Services Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. North America
8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.7. Sweden
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Competitive Scenario
8.5.8.3. Regulatory Framework
8.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Competitive Scenario
8.5.9.3. Regulatory Framework
8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. Thailand
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.7. Australia
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Competitive Scenario
8.8.4.3. Regulatory Framework
8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Competitive Scenario
8.8.5.3. Regulatory Framework
8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.1.1. Market Leaders
9.1.2. Emerging Players
9.2. Company Market Share/Assessment Analysis, 2024
9.3. Company Profiles
9.3.1. Laboratory Corporation of America Holdings
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Charles River Laboratories
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Eurofins Scientific
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Celerion
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. ICON plc.
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Parexel International (MA) Corporation
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Proteome Sciences
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. GHO Capital
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Thermo Fisher Scientific Inc.
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Evotec
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives
관련자료
